NANOBIOTIX (EPA:NANO) | WebDisclosure

PRESS RELEASE

published on 09/17/2025 at 22:15, 4 months 24 days ago

NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
Nanobiotix announces new results from a Phase 1 study evaluating JNJ-1900 (NBTXR3) in combination with immune checkpoint inhibitors as a 2L+ therapy for patients with primary cutaneous melanoma resistant to anti-PD-1. Favorable safety profile and early efficacy signals observed

Melanoma NANOBIOTIX Immune Checkpoint Inhibitors Phase 1 Study JNJ-1900
PRESS RELEASE

published on 09/17/2025 at 22:15, 4 months 24 days ago

NANOBIOTIX annonce de nouveaux résultats de Phase 1 évaluant JNJ-1900 (NBTXR3) en combinaison avec des inhibiteurs de points de contrôle en traitement de deuxième ligne ou plus chez des patients atteints de mélanome cutané résistant aux anti-P
NanoBiotix annonce de nouveaux résultats de phase 1 évaluant JNJ-1900 (NBTXR3) en combinaison avec des inhibiteurs de points de contrôle en traitement de deuxième ligne ou plus chez des patients atteints de mélanome cutané résistant aux anti-PD-1

NANOBIOTIX Phase 1 Inhibiteurs De Points De Contrôle JNJ-1900 Mélanome Cutané
BRIEF

published on 09/12/2025 at 19:05, 4 months 29 days ago

Nanobiotix Announces Voting Rights and Share Capital Details

Voting Rights Shares Euronext Nasdaq NANOBIOTIX
BRIEF

published on 09/12/2025 at 19:05, 4 months 29 days ago

Nanobiotix annonce les droits de vote et le détail du capital social

Euronext Actions Nasdaq Droit De Vote NANOBIOTIX
PRESS RELEASE

published on 09/12/2025 at 19:00, 4 months 29 days ago

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Communiqué de presse sur le nombre total de droits de vote et d'actions de Nanobiotix. Informations financières clés et activités de l'entreprise

Droits De Vote Capital Social Biotechnologie Actions NANOBIOTIX
PRESS RELEASE

published on 09/12/2025 at 19:00, 4 months 29 days ago

Voting Rights and Shares Capital of the Company
Nanobiotix releases voting rights and shares capital details. The company is listed on Euronext Paris and Nasdaq, pioneering biotechnology for treatment advancements

Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
BRIEF

published on 09/02/2025 at 22:20, 5 months 9 days ago

Nanobiotix à la conférence H.C. Wainwright Global Investment

Biotechnologie Investisseurs Conference NANOBIOTIX Thérapeutiques
BRIEF

published on 09/02/2025 at 22:20, 5 months 9 days ago

Nanobiotix at the HC Wainwright Global Investment Conference

Investors Biotechnology Conference Therapeutics NANOBIOTIX
PRESS RELEASE

published on 09/02/2025 at 22:15, 5 months 9 days ago

Nanobiotix participera à la conférence investisseurs annuelle H.C. Wainwright global investment
Nanobiotix participe à la conférence investisseurs annuelle H.C. Wainwright Global Investment pour présenter ses avancées en biotechnologie pour le traitement du cancer et d'autres maladies

Biotechnologie Conférence Investisseurs Cancer NANOBIOTIX Maladies
PRESS RELEASE

published on 09/02/2025 at 22:15, 5 months 9 days ago

Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Nanobiotix to participate in H.C. Wainwright 27th Annual Global Investment Conference with a fireside chat featuring company management. Nanoparticle-based treatments for cancer and major diseases

Fireside Chat NANOBIOTIX H.C. Wainwright Conference Late-stage Biotechnology Nanoparticle-based Treatments

Published on 02/12/2026 at 17:00, 1 hour 47 minutes ago

Diamcor Provides Update on Discharge of Security and Indebtedness, and Granting of Extension of Time to Hold the 2025 Annual General Meeting
Published on 02/12/2026 at 15:00, 3 hours 47 minutes ago

Onco-Innovations Announces Amendment to Private Placement Pricing
Published on 02/12/2026 at 14:30, 4 hours 17 minutes ago

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
Published on 02/12/2026 at 14:30, 4 hours 17 minutes ago

Loar Holdings Inc. Announces Date and Time for Fourth Quarter and Full Year 2025 Earnings Conference Call
Published on 02/12/2026 at 14:22, 4 hours 25 minutes ago

Worksport Confirms Government Evaluation of Aetherlux(TM) Heat Pump for Potential Long-Term Supply Deal; Certification Accelerated

View all ACCESSWIRE

Published on 02/12/2026 at 17:51, 55 minutes ago

POS-Transaction in Own Shares
Published on 02/12/2026 at 17:45, 1 hour 2 minutes ago

ENOGIA: Chiffre d’affaires de l’exercice 2025 : +57% (12,6 M€)
Published on 02/12/2026 at 17:45, 1 hour 2 minutes ago

ENOGIA: FY 2025 revenue: +57% (€12.6 million)
Published on 02/12/2026 at 17:31, 1 hour 15 minutes ago

R. STAHL launches development program for the future and withdraws from employer association
Published on 02/12/2026 at 17:08, 1 hour 39 minutes ago

Siltronic releases its guidance for financial year 2026

View all EQS

Published on 02/12/2026 at 17:58, 48 minutes ago

TF1 group 2025 full-year results
Published on 02/12/2026 at 17:58, 48 minutes ago

Résultats annuels 2025 du groupe TF1
Published on 02/12/2026 at 17:45, 1 hour 2 minutes ago

MR.BRICOLAGE SA: ENTERING INTO A NEW SYNDICATED CREDIT FACILITY
Published on 02/12/2026 at 17:45, 1 hour 2 minutes ago

Mr.Bricolage : Mise en place d'un nouveau contrat de crédit
Published on 02/12/2026 at 17:45, 1 hour 2 minutes ago

Chiffre d’affaires des 9 premiers mois de l’exercice 2025/2026

View all LES ECHOS COMFI WIRE

News